
BioFinland Member
Herantis Pharma Plc

Company name
Herantis Pharma Plc
Address
Bertel Jungin aukio 1, FI-02600 Espoo
Telephone
+358 9 222 1195
Employees
10-49
Founded
2008
Contact person
antti.vuolanto at herantis.com
CEO
Antti Vuolanto
Web site
Main categories
Drug Discovery and Development / Drug Delivery, Pharmaceutical
Last updated
5 February 2019
Company profile
Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine and unmet clinical needs. Our clinical stage assets CDNF and Lymfactin® are based on globally leading scientific research in their fields. They both aim at breakthrough in the treatment of severe diseases: CDNF in neurodegenerative diseases such as Parkinson’s disease; and Lymfactin® in breast cancer associated lymphedema with potential also in other lymphedemas. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.